Neuberger Berman Group
CRNX

Neuberger Berman Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Neuberger Berman Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
7,058
+20
+0.3% +$743 ﹤0.01% 2069
2026
Q1 		$256K Sell
7,038
-175,150
-96% -$7.82M ﹤0.01% 1904
2025
Q4 		$8.48M Buy
182,188
+115,040
+171% +$5.12M 0.01% 844
2025
Q3 		$2.8M Buy
+67,148
New +$2.15M ﹤0.01% 1087

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's CRNX Position: Q2 2026 in Review

Neuberger Berman Group increased its Crinetics Pharmaceuticals (CRNX) stake by 0.28% in Q2 2026, buying an estimated $743 and bringing the position to 7,058 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Neuberger Berman Group first reported a position in CRNX in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.48M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Neuberger Berman Group held 7,058 shares of Crinetics Pharmaceuticals worth $264K as of Q2 2026.
  • Neuberger Berman Group bought 20 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $743.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2069 holding.
  • Neuberger Berman Group first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Neuberger Berman Group's Crinetics Pharmaceuticals position peaked at $8.48M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.